The gut microbiome in Alzheimer’s disease: what we know and what remains to be explored

被引:0
作者
Sidhanth Chandra
Sangram S. Sisodia
Robert J. Vassar
机构
[1] Northwestern University Feinberg School of Medicine,Ken and Ruth Davee Department of Neurology
[2] Northwestern University Feinberg School of Medicine,Medical Scientist Training Program
[3] University of Chicago,Department of Neurobiology
来源
Molecular Neurodegeneration | / 18卷
关键词
Gut microbiome; Amyloid; Tau; Neuroinflammation; Peripheral immunity; Human; Mouse; Therapeutics; Diet; Sleep; Exercise;
D O I
暂无
中图分类号
学科分类号
摘要
Alzheimer’s disease (AD), the most common cause of dementia, results in a sustained decline in cognition. There are currently few effective disease modifying therapies for AD, but insights into the mechanisms that mediate the onset and progression of disease may lead to new, effective therapeutic strategies. Amyloid beta oligomers and plaques, tau aggregates, and neuroinflammation play a critical role in neurodegeneration and impact clinical AD progression. The upstream modulators of these pathological features have not been fully clarified, but recent evidence indicates that the gut microbiome (GMB) may have an influence on these features and therefore may influence AD progression in human patients. In this review, we summarize studies that have identified alterations in the GMB that correlate with pathophysiology in AD patients and AD mouse models. Additionally, we discuss findings with GMB manipulations in AD models and potential GMB-targeted therapeutics for AD. Lastly, we discuss diet, sleep, and exercise as potential modifiers of the relationship between the GMB and AD and conclude with future directions and recommendations for further studies of this topic.
引用
收藏
相关论文
共 1147 条
  • [1] Long JM(2019)Alzheimer Disease: an update on pathobiology and treatment strategies Cell 179 312-339
  • [2] Holtzman DM(2011)Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination Nature 479 538-541
  • [3] Berer K(2016)Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson's disease Cell 167 1469-80.e12
  • [4] Mues M(2021)Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease Mol Neurodegener 16 6-1560
  • [5] Koutrolos M(2016)Antibiotic-induced perturbations in gut microbial diversity influences neuro-inflammation and amyloidosis in a murine model of Alzheimer's disease Sci Rep 6 30028-68
  • [6] Rasbi ZA(2017)Antibiotic-induced perturbations in microbial diversity during post-natal development alters amyloid pathology in an aged APP(SWE)/PS1(ΔE9) murine model of Alzheimer's disease Sci Rep 7 10411-1346
  • [7] Boziki M(2019)Sex-specific effects of microbiome perturbations on cerebral Aβ amyloidosis and microglia phenotypes J Exp Med 216 1542-643
  • [8] Johner C(2021)Gut microbiota–driven brain Aβ amyloidosis in mice requires microglia J Exp Med 219 19-62
  • [9] Sampson TR(2022)Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease Mol Neurodegener 17 60-788
  • [10] Debelius JW(2017)Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly Neurobiol Aging 49 13537-390